EGFR-tested Non-Small-Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer: Demographics, Treatment and Outcome Characteristics of Patient Cases in a Community-Based Setting.
Phase of Trial: Phase IV
Latest Information Update: 10 Mar 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 04 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.